Engineers Gate Manager LP boosted its stake in Phibro Animal Health Corp (NASDAQ:PAHC) by 65.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,085 shares of the company’s stock after acquiring an additional 9,161 shares during the quarter. Engineers Gate Manager LP’s holdings in Phibro Animal Health were worth $990,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Victory Capital Management Inc. grew its position in shares of Phibro Animal Health by 27.7% during the 3rd quarter. Victory Capital Management Inc. now owns 10,337 shares of the company’s stock worth $443,000 after purchasing an additional 2,242 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of Phibro Animal Health by 44.1% during the 3rd quarter. Acadian Asset Management LLC now owns 332,497 shares of the company’s stock worth $14,263,000 after purchasing an additional 101,683 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Phibro Animal Health during the 3rd quarter worth approximately $4,444,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Phibro Animal Health during the 3rd quarter worth approximately $1,290,000. Finally, Confluence Investment Management LLC acquired a new position in shares of Phibro Animal Health during the 3rd quarter worth approximately $2,871,000. 47.95% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ PAHC opened at $37.10 on Friday. The company has a current ratio of 3.26, a quick ratio of 1.66 and a debt-to-equity ratio of 1.62. The company has a market cap of $1.56 billion, a P/E ratio of 21.32, a PEG ratio of 3.34 and a beta of 0.82. Phibro Animal Health Corp has a 1 year low of $32.05 and a 1 year high of $54.62.
Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $0.39 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.42 by ($0.03). The firm had revenue of $200.20 million for the quarter, compared to analyst estimates of $203.99 million. Phibro Animal Health had a return on equity of 38.91% and a net margin of 7.89%. The business’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.38 EPS. Equities analysts expect that Phibro Animal Health Corp will post 1.7 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 19th. Investors of record on Wednesday, November 28th will be given a dividend of $0.12 per share. This is a positive change from Phibro Animal Health’s previous quarterly dividend of $0.10. The ex-dividend date is Tuesday, November 27th. This represents a $0.48 annualized dividend and a dividend yield of 1.29%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 22.99%.
A number of research analysts have issued reports on PAHC shares. Morgan Stanley increased their target price on shares of Phibro Animal Health from $36.00 to $46.00 and gave the stock an “underweight” rating in a research report on Wednesday, August 29th. BidaskClub lowered shares of Phibro Animal Health from a “hold” rating to a “sell” rating in a research report on Tuesday, September 18th. Finally, Zacks Investment Research upgraded shares of Phibro Animal Health from a “sell” rating to a “buy” rating and set a $53.00 target price on the stock in a research report on Thursday, August 30th. Four research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $43.50.
In related news, CEO Jack Bendheim sold 10,000 shares of the stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $50.03, for a total transaction of $500,300.00. Following the sale, the chief executive officer now owns 60,000 shares in the company, valued at approximately $3,001,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel M. Bendheim sold 2,500 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $44.30, for a total transaction of $110,750.00. Following the sale, the vice president now owns 2,500 shares in the company, valued at approximately $110,750. The disclosure for this sale can be found here. Insiders have sold a total of 143,020 shares of company stock worth $6,967,571 in the last quarter. 50.29% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/11/engineers-gate-manager-lp-boosts-position-in-phibro-animal-health-corp-pahc.html.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Further Reading: Technical Analysis
Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corp (NASDAQ:PAHC).
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.